Forward et al(5) studied goserelin (GOS) plus anastrozole (ANA) as a second-line endocrine therapy in 16 premenopausal women with advanced breast cancer who had previously received an LH-RH analogue plus TAM. This evidence concerns the gene GNRH1 and breast cancer.